Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.59 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | CDC25A | P30304 | 3/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.64 |
| ▸ | VDR | P11473 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | PGR | P06401 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698818 | 0.96 | MAPT (0.69) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL260762 | 0.96 | MAPT (0.69) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL6842113 | 0.96 | MAPT (0.69) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL10034118 | 0.96 | MAPT (0.69) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL233428 | 0.89 | MAPT (0.69) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL10594420 | 0.87 | VDR (0.57) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL4960177 | 0.85 | MAPT (0.74) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL10034122 | 0.85 | MAPT (0.74) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL8003899 | 0.85 | MAPT (0.74) | MAPTMEN1KMT2ACDC25AADORA3 | |
| SCHEMBL232217 | 0.85 | MAPT (0.74) | MAPTMEN1KMT2ACDC25AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070513-A1 | Treatment of inflammatory bowel disease with vitamin D compounds | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-03-31 | — | — | US | claimed |
| US-20030188756-A1 | Treatment of inflammatory bowel disease with vitamin d compounds | PENN STATE RESEARCH FOUNDATION, THE | 2003-10-09 | — | — | US | claimed |
| EP-1233942-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-08-28 | — | — | EP | claimed |
| WO-2001042205-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1796680-A2 | METHODS OF TREATING SYMPTOMS OF MULTIPLE SCLEROSIS USING VITAMIN D AND RELATED COMPOUNDS | Teva Pharmaceutical Industries Ltd (IL) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006032053-A2 | METHODS OF TREATING SYMPTOMS OF MULTIPLE SCLEROSIS USING VITAMIN D AND RELATED COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-03-23 | — | — | WO | disclosed |
| US-6989377-B2 | Treating vitamin D responsive diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050070513-A1 | Treatment of inflammatory bowel disease with vitamin D compounds | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-03-31 | — | — | US | disclosed |
| US-6858595-B2 | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease | WISCONSIN ALUMNI RESEARCH ASSOCIATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1240136-A4 | USE OF BIOLOGICALLY ACTIVE VITAMIN D COMPOUNDS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE | WISCONSIN ALUMNI RES FOUND (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003106629-A2 | TREATING VITAMIN D RESPONSIVE DISEASES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030188756-A1 | Treatment of inflammatory bowel disease with vitamin d compounds | PENN STATE RESEARCH FOUNDATION, THE | 2003-10-09 | — | — | US | disclosed |
| EP-1240136-A1 | USE OF BIOLOGICALLY ACTIVE VITAMIN D COMPOUNDS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE | Northern Lights Pharmaceuticals, LLC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1233942-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6358939-B1 | ADMINISTERING 1,25-DIHYDROXYVITAMIN D TO TREAT ULCERATIVE COLITIS AND CROHN*S DISEASE | NORTHERN LIGHTS PHARMACEUTICALS, LLC | 2002-03-19 | — | — | US | disclosed |
| EP-0880350-B1 | MULTIPLE SCLEROSIS TREATMENT | WISCONSIN ALUMNI RES FOUND (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001046132-A1 | USE OF BIOLOGICALLY ACTIVE VITAMIN D COMPOUNDS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE | NORTHERN LIGHTS PHARMACEUTICALS, LLC (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001042205-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0880350-A1 | MULTIPLE SCLEROSIS TREATMENT | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029740-A1 | MULTIPLE SCLEROSIS TREATMENT | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070513-A1 | Treatment of inflammatory bowel disease with vitamin D compounds | VDR, CYP24A1, CYP2R1 | AGTR1 4163/4885OPRK1 1876/4885MAPT 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.